Polycythemia Vera Pipeline Review 2017 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Polycythemia Vera - Pipeline Review, H1 2017" report to their offering.

Polycythemia Vera - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Polycythemia Vera (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Polycythemia Vera (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Polycythemia Vera and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 3, 3 and 3 respectively.

Polycythemia Vera (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Polycythemia Vera - Overview
  3. Polycythemia Vera - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Products under Development by Companies
  7. Polycythemia Vera - Therapeutics Assessment
  8. Assessment by Target
  9. Assessment by Mechanism of Action
  10. Assessment by Route of Administration
  11. Assessment by Molecule Type
  12. Polycythemia Vera - Companies Involved in Therapeutics Development

- Bristol-Myers Squibb Company

- F. Hoffmann-La Roche Ltd

- Galena Biopharma Inc

- Gilead Sciences Inc

- Italfarmaco SpA

- Karus Therapeutics Ltd

- Nerviano Medical Sciences Srl

- Novartis AG

- PharmaEssentia Corp

For more information about this report visit http://www.researchandmarkets.com/research/ztndxn/polycythemia_vera

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Hematological Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Hematological Drugs